Are ibogaine clinical trials available in the United States in 2026?

Yes, U.S. clinical research is active or preparing through academic and state-funded programs, especially after Texas awarded $50 million to UTHealth Houston and UTMB Health. Availability is limited and depends on enrollment criteria, location, medical screening, and IND-authorized protocols.

Is ibogaine FDA-approved for opioid addiction?

No. As of May 2026, ibogaine remains Schedule I and is not FDA-approved for opioid use disorder, alcohol use disorder, PTSD, or any other indication. Legal U.S. access is generally limited to clinical trials or rare expanded-access pathways.

When could ibogaine be FDA-approved?

The realistic approval window cited in 2026 analyses is 2030–2032. Breakthrough Therapy designation could accelerate review, but full approval still requires rigorous Phase 2b/3 or Phase 3 evidence and a safety package acceptable to the FDA.

What is the biggest safety concern in ibogaine trials?

Cardiac safety, especially QTc prolongation, is the central concern. Serious protocols use baseline ECG screening, medication review, laboratory testing, and continuous ECG telemetry during the acute 24–38 hour period.

Does ibogaine cure addiction in one treatment?

No. Observational studies suggest some patients experience months of reduced craving or abstinence, but ibogaine is not a guaranteed or permanent cure. Long-term outcomes depend on follow-up care, psychotherapy, social support, and individual medical and psychiatric factors.

How does ibogaine differ from methadone or buprenorphine?

Methadone and buprenorphine are evidence-based maintenance medications taken regularly and known to reduce overdose risk. Ibogaine is being studied as an intensive episodic intervention that may suppress withdrawal and craving without daily dosing. It is a different treatment model, not a universal replacement.

Can I legally receive ibogaine treatment outside a U.S. trial?

Not in routine U.S. medical care. Some people travel to countries where ibogaine clinics operate, such as Mexico, but those treatments are not FDA-approved and may vary widely in screening, monitoring, manufacturing quality, and follow-up.

Who should not consider ibogaine clinical trial enrollment?

People with arrhythmias, prolonged QT syndrome, serious cardiac disease, uncontrolled hypertension, severe liver disease, active psychosis, unstable bipolar disorder, or interacting medications may be excluded. Only a qualified trial team can determine eligibility.

What should I ask a trial coordinator before enrolling?

Ask whether the study is IND-authorized, what cardiac monitoring is used, what medications are excluded, how long observation lasts, what endpoints are measured, and what recovery support is provided after discharge.

Funded Trials Hub | Ibogatrack

01 / starting point

What ibogaine clinical trials are actually testing

Clinical trials are structured research studies. For people researching ibogaine, the useful question is not simply whether a study exists, but what it is designed to examine: a particular condition, a protocol, a safety measure, a dose approach, or a follow-up period. The ClinicalTrials.gov study registry describes trial records with details such as purpose, status, eligibility, locations, and outcome measures.

A funded study can indicate that an organization has chosen to investigate a defined question. It does not establish that ibogaine is approved, available, appropriate for an individual, or without risk. For broader context on the subject and its Texas-specific practical questions, the Ibogatrack overview of ibogaine research keeps evidence, safety, legality, and practical considerations in view together.

Study design

Look for the question being asked, who may participate, what is compared, and how outcomes are described.

Funding context

Note the named sponsor or collaborator without treating funding as a substitute for results or independent review.

Calm research setting supporting careful review of ibogaine clinical trial records — Trial records are a starting document: useful for identifying the research question and the limits of what a listing can show.

02 / reading a record

How to read a trial record without overreading it

Start with the official title and status, then move slowly through the sponsor, recruitment information, inclusion and exclusion criteria, listed interventions, and primary outcomes. A record may change as a study develops. “Recruiting,” “active,” “completed,” or “withdrawn” describe study status; none of those labels alone tells a reader what the final evidence will show.

The U.S. Food and Drug Administration explains that clinical trials answer specific research questions under protocols intended to protect participants and collect information. That distinction matters for ibogaine: a listing is not a treatment recommendation, and eligibility language is not an invitation to self-screen.

Where a registry identifies a sponsor or source of support, keep the language precise. A named funder helps locate responsibility for a project; it does not predict results, replace peer review, or settle legal questions. The Texas state-funded timeline can help readers place public research activity and policy developments in sequence.

03 / practical comparison

Separate a trial listing from a clinical claim

People often encounter a mix of registry entries, announcements, policy discussions, and personal accounts. These sources do different jobs. A trial record describes planned or ongoing research. A completed study may later produce a paper. A regulatory decision is a different category again. The basic structure of a clinical trial includes phases and methods that are designed to answer bounded questions rather than to make universal promises.

Registry entry

Useful for study aims, participation rules, locations, status, sponsor, and planned outcome measures.

Study results

Useful when the methods, findings, limitations, and follow-up are available for careful review.

Policy material

Useful for understanding the legal and public-funding context, especially when the question is specific to Texas.

“A study exists” and “a conclusion has been established” are not the same statement.

04 / safety and legality

Keep safety and Texas legality in the same frame

For people researching ibogaine in Texas, safety and legality are not side notes to a trial search. They shape how any study description should be understood. Trial protocols may include screening and monitoring procedures because research is designed around defined conditions; those procedures should not be generalized beyond the research setting.

Federal scheduling is one part of the legal backdrop. The Drug Enforcement Administration’s scheduling overview explains the federal framework used for controlled substances. Questions about Texas policy, proposed funding, or state-level activity deserve their own source trail rather than assumptions drawn from a registry entry.

Readers comparing practical questions can also consult the Texas ibogaine bill resource for legislation-focused context. This page is an information resource, not medical or legal advice, and a clinical trial listing should never be used to make a personal medical decision.

05 / common questions

Questions to carry into a trial search

Does a trial listing mean ibogaine is approved?

No. A registered study is a research activity. It does not itself establish approval, availability, or suitability for a person researching ibogaine in Texas.

What should readers look for in a funded trial record?

Look for the study purpose, sponsor or funder, recruitment status, eligibility criteria, locations, listed outcomes, and contact route supplied by the registry. Treat each field as information about the study, not a personal recommendation.

Why do safety details matter in ibogaine research?

Ibogaine research requires close attention to screening, monitoring, and protocol design. A study description can clarify what is being evaluated, but it is not personal medical or legal advice. The Texas safety policy brief is a separate place to consider the policy-facing safety questions.

A measured next step

Use records to ask better questions, not to rush toward conclusions.

Keep the source, date, research status, and Texas context together. That approach leaves room for uncertainty while making a funded trial record more useful for people researching ibogaine.

Ibogatrack is an independent information resource for people researching ibogaine.